---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-015876"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:19:11.819858+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences receives Nasdaq deficiency letter for bid price below $1.00

## Summary
- Nasdaq notified on April 24, 2023 that DTIL common stock closed below $1.00 for 30 consecutive business days.
- Company has 180 days, until October 23, 2023, to regain compliance by having bid price ≥$1.00 for 10 consecutive days.
- If not compliant by deadline, DTIL may request transfer to Nasdaq Capital Market and obtain an additional 180-day period.
- Company may consider a reverse stock split to cure the deficiency, but no assurance of regaining compliance.

## SEC filing metadata
- accession: 0000950170-23-015876
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023015876/0000950170-23-015876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023015876/dtil-20230424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-015876
- JSON: https://secwatch.observer/filing/0000950170-23-015876.json
- Plain text: https://secwatch.observer/filing/0000950170-23-015876.txt

## Key facts
- Listing & Compliance Notices
  PRECISION BIOSCIENCES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: April 24, 2023, Precision BioSciences, Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017023015876/0000950170-23-015876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.